Compare Amylx Pharmaceuticals Inc (AMLX) vs United Parcel Service Inc (UPS) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

UPS trades at $104.48, up 1.24% daily, with a bearish technical signal but recent earnings beats. Revenue declined to $88.66B in 2025, with net income margin at 5.08%, while valuation ratios like P/E of 19.42 and P/S of 0.99 suggest moderate pricing. The company maintains a strong dividend yield, with recent payouts of $1.64 per share, and analyst consensus is mixed amid cost-cutting efforts and Amazon volume reset.

Outlook is cautious due to margin pressures and competitive threats, but upside exists if operational efficiencies materialize. Risks include high debt-to-asset ratio of 33.02% and volatile cash flows. Analysts target $117.90 on average, implying potential growth, but investor sentiment remains divided given bearish technical trends.